ADC Therapeutics (ADCT) Net Income (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Net Income of -$33.0 million for Q1 2026, up 14.6% year-on-year from -$28.8 million in Q1 2025, and up 19.52% on a QoQ basis from -$41.0 million in Q3 2025.
ADC Therapeutics (ADCT) Net Income (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Net Income for 7 consecutive years, with -$33.0 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income rose 14.6% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.6 million (down 10.42% YoY) and the FY2022 annual result came in at -$152.6 million, up 33.84% from the prior year.
- Net Income grew to -$33.0 million in Q1 2026 per ADCT's latest filing, from -$41.0 million in the prior quarter.
- Over the last five years, Net Income for ADCT reached as high as -$16.7 million in Q1 2022 and fell as low as -$64.4 million in Q2 2022.
- A 5-year average of -$42.7 million and a median of -$44.5 million in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income surged 67.67% — and 2023, when it sank 256.68%.
- Year by year, Net Income stood at -$18.2 million in 2022, then slumped by 149.56% to -$45.3 million in 2023, then climbed by 3.52% to -$43.7 million in 2024, then increased by 6.28% to -$41.0 million in 2025, then climbed by 19.52% to -$33.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$33.0 million, -$41.0 million, and -$56.6 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | -32.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.97 Mn |
| Sep 30, 2025 | -40.97 Mn |
| Jun 30, 2025 | -56.65 Mn |
| Mar 31, 2025 | -38.60 Mn |
| Sep 30, 2024 | -43.71 Mn |
| Jun 30, 2024 | -35.95 Mn |
| Mar 31, 2024 | -46.00 Mn |
| Sep 30, 2023 | -45.30 Mn |
| Jun 30, 2023 | -48.20 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -18.15 Mn |
| Sep 30, 2022 | -50.61 Mn |
| Jun 30, 2022 | -64.37 Mn |
| Mar 31, 2022 | -16.66 Mn |
| Dec 31, 2021 | -35.52 Mn |
| Sep 30, 2021 | -71.55 Mn |
| Jun 30, 2021 | -72.57 Mn |
| Mar 31, 2021 | -51.53 Mn |
| Dec 31, 2020 | -56.26 Mn |
| Sep 30, 2020 | -20.33 Mn |